
Removal of the “X-Waiver” Requirement
Fact SheetOpioid Misuse and Overdose PreventionHarm Reduction Legal ProjectHarm Reduction Legal Project ResourcesSubstance Use Prevention and Harm ReductionOn December 29, 2022, President Biden signed the 2023 Consolidation Appropriations Act (“the Act”) into law.1 Among many other provisions, the Act included substantial regulatory changes to remove barriers and promote access to evidence-based treatment of substance use disorders (“SUD”). In particular, the Act removed legal barriers to the prescription of buprenorphine for opioid use disorder (“OUD”). It also requires almost all prescribers to obtain training in the identification and treatment of SUD. Although it will add a small educational burden to most providers who prescribe controlled substances, these changes should make it easier for all prescribers to provide buprenorphine treatment to individuals with OUD and significantly expand the base of prescribers who receive at least some training in identifying and treating individuals with SUD.